Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

ABSTRACT:

Background

Prostate cancer remains the second leading cause of cancer related death in men. Immune check point blocking antibodies have revolutionized treatment of multiple solid tumors, but results in prostate cancer remain marginal. Previous reports have suggested that local therapies, in particular cryoablation might increase tumor immunogenicity. In this work, we examine potential synergism between tumor cryoabalation and check point blocking antibodies.

Methods

FVB/NJ mice were injected subcutaneously into each flank with either 1 × 10⁶ or 0.2 × 10⁶ isogenic hormone sensitive Myc-Cap cells to establish synchronous grafts. Mice were treated with four intraperitoneal injections of anti-PD-1 (10 mg/kg), anti-CTLA-4 (1 mg/kg), or isotype control antibo

SUBMITTER: Benzon B 

PROVIDER: S-EPMC5990963 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature